PreciseDx raises $10.75M in funding

By LabPulse.com staff writers

January 12, 2022 -- Cancer risk stratification company PreciseDx announced that it has raised $10.75 million in series A funding. The funds will be used to support the ongoing development and commercialization of its (artificial intelligence) AI-powered risk stratification platform.

Also, the company announced the appointment of Wayne Brinster to CEO, which was effective September 2021. Brinster has more than 30 years of experience and held management positions at MedTest, Wheaton Industries/DWK, Synthon Pharmaceuticals, and Becton Dickinson.


Copyright © 2022 LabPulse.com

Last Updated bc 1/12/2022 5:32:16 PM